Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-27T14:30:22.976Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety of HES 130/0.4 (Voluven®) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial

Published online by Cambridge University Press:  01 December 2008

G. Godet ,
J.-J. Lehot ,
G. Janvier ,
A. Steib ,
V. De Castro  and
P. Coriat
G. Godet*
Affiliation:
Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, Paris, France
J.-J. Lehot
Affiliation:
Hospices Civils de Lyon, Centre Hospitalo-Universitaire, Department of Anaesthesiology and Critical Care, Lyon, France
G. Janvier
Affiliation:
Centre Hospitalo-Universitaire de Bordeaux, Department of Anaesthesiology and Critical Care, Pessac, France
A. Steib
Affiliation:
Hôpitaux Universitaires de Strasbourg, Department of Anaesthesiology and Critical Care, Strasbourg, France
V. De Castro
Affiliation:
Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, Paris, France
P. Coriat
Affiliation:
Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, Paris, France
*
Correspondence to: Gilles Godet, Département d’Anesthésie Réanimation 2, CHU Rennes, Hôpital Pontchaillou, 2 rue Henri Le Guilloux, 35033-Rennes Cedex 9, France. E-mail: gilles.godet@chu-rennes.fr; Tel: +33 2 99 28 43 21; Fax: +33 2 99 28 25 50
Get access

Summary

Background and objective

Patients with impaired renal function are at risk of developing renal dysfunction after abdominal aortic surgery. This study investigated the safety profile of a recent medium-molecular-weight hydroxyethyl starch (HES) preparation with a low molar substitution (HES 130/0.4) in this sensitive patient group.

Methods

Sixty-five patients were randomly allocated to receive either 6% hydroxyethyl starch (Voluven®; n = 32) or 3% gelatin (Plasmion®; n = 33) for perioperative volume substitution. At baseline, renal function was impaired in all study patients as indicated by a measured creatinine clearance < 80 mL min−1. The main renal safety parameter was the peak increase in serum creatinine up to day 6 after surgery.

Results

Both treatment groups were compared for non-inferiority (pre-defined non-inferiority range hydroxyethyl starch < gelatin + 17.68 μmol L−1 or 0.2 mg dL−1). Other renal safety parameters included minimum postoperative creatinine clearance, incidence of oliguria and adverse events of the renal system. Baseline characteristics, surgical procedures and the mean total infusion volume were comparable. Non-inferiority of hydroxyethyl starch vs. gelatin could be shown by means of the appropriate non-parametric one-sided 95% CI for the difference hydroxyethyl starch − gelatin [−∞, 11 μmol L−1]. Oliguria was encountered in three patients of the hydroxyethyl starch and four of the gelatin treatment group. One patient receiving gelatin required dialysis secondary to surgical complications. Two patients of each treatment group died.

Conclusion

As we found no drug-related adverse effects of hydroxyethyl starch on renal function, we conclude that the choice of the colloid had no impact on renal safety parameters and outcome in patients with decreased renal function undergoing elective abdominal aortic surgery.

Keywords

CHRONIC RENAL INSUFFICIENCYSURGERY AORTICHYDROXYETHYL STARCHGELATINPOSTOPERATIVE ACUTE RENAL FAILURE
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 25 , Issue 12 , December 2008 , pp. 986 - 994
Copyright
copyright © European Society of Anaesthesiology 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Awad, RW, Barham, WJ, Taylor, DN, Woodward, DA, Bullen, BR. The effect of infrarenal aortic reconstruction on glomerular filtration rate and effective renal plasma flow. Eur J Vasc Surg 1992; 6: 362–367.Google Scholar
2.Svensson, LG, Coselli, JS, Safi, HJ, Hess, KR, Crawford, ES. Appraisal of adjuncts to prevent acute renal failure after surgery on the thoracic or thoracoabdominal aorta. J Vasc Surg 1989; 10: 230–239.CrossRefGoogle ScholarPubMed
3.Svensson, LG, Crawford, ES, Hess, KR, Coselli, JS, Safi, HJ. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993; 17: 357–368; discussion 368–370.CrossRefGoogle ScholarPubMed
4.Boldt, J, Müller, M, Mentges, D, Papsdorf, M. Hempelmann GVolume therapy in the critically ill: is there a difference? Intensive Care Med 1998; 24: 28–36.CrossRefGoogle ScholarPubMed
5.Schortgen, F, Deye, N, Brochard, L; CRYCO Study Group. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 2004; 30: 2222–2229.CrossRefGoogle ScholarPubMed
6.Davidson, IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006; 23: 721–738.Google Scholar
7.Treib, J, Baron, JF, Grauer, MT, Strauss, RG. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25: 258–268.Google Scholar
8.Jungheinrich, C, Neff, TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005; 44: 681–699.Google Scholar
9.Dieterich, HJ. Recent developments in European colloid solutions. J Trauma 2003; 54: S26–S30.Google ScholarPubMed
10.Waitzinger, J, Bepperling, F, Pabst, G, Opitz, J. Hydroxyethyl starch (HES) 130/0.4, a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003; 4: 149–157.Google Scholar
11.Waitzinger, J, Bepperling, F, Pabst, B, Opitz, J, Müller, M, Baron, JF. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 151–160.Google Scholar
12.Jungheinrich, C, Sauermann, W, Bepperling, F, Vogt, NH. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D 2004; 5: 1–9.CrossRefGoogle ScholarPubMed
13.Gallandat Huet, RC, Siemons, AW, Baus, D et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000; 47: 1207–1215.Google Scholar
14.Langeron, O, Doelberg, M, Ang, ET, Bonnet, F, Capdevila, X, Coriat, P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92: 855–862.CrossRefGoogle Scholar
15.Schortgen, F, Lacherade, JC, Bruneel, F et al. Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomized study. Lancet 2001; 357: 911–916.Google Scholar
16.Boldt, J, Godet, G, Bernal, W, Wendon, JA. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 2001; 358: 581–583.Google Scholar
17.Legendre, C, Thervet, E, Page, B, Percheron, A, Noel, LH, Kreis, H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 248–249.CrossRefGoogle ScholarPubMed
18.Ebcioglu, Z, Cohen, DJ, Crew, RJ et al. Osmotic nephrosis in a renal transplant recipient. Kidney Int 2006; 70: 1873–1876.Google Scholar
19.Boldt, J, Brenner, T, Lehmann, A, Lang, J, Kumle, B, Werling, C. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 2003; 29: 763–769.CrossRefGoogle ScholarPubMed
20.Jungheinrich, C, Scharpf, R, Wargenau, M, Bepperling, F. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild to severe renal impairment. Anesth Analg 2002; 95: 544–551.Google Scholar
21.Boldt, J, Brosch, C, Ducke, M, Papsdorf, M, Lehmann, A. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 2007; 35: 2740–2746.Google Scholar
22.Lenz, K, Schimetta, W, Polz, W, Kröll, W, Gruy-Kapral, C, Magometschnigg, D. Intestinal elimination of hydroxyethyl starch? Intensive Care Med 2000; 26: 733–739.Google Scholar
23.Kumle, B, Boldt, J, Piper, S, Schmidt, C, Suttner, S, Salopek, S. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Analg 1999; 89: 1124–1130.CrossRefGoogle ScholarPubMed
24.Cittanova, ML, Mavre, J, Riou, B, Coriat, P. Long-term follow-up of transplanted kidneys according to plasma volume expander of kidney donors. Intensive Care Med 2001; 27: 1830.Google Scholar
25.Cittanova, ML, Leblanc, I, Legendre, C, Mouquet, C, Riou, B, Coriat, P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620–1622.CrossRefGoogle ScholarPubMed
26.Pillebout, E, Nochy, D, Hill, G et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005; 5: 1120–1129.Google Scholar
27.Randhawa, PS, Shapiro, R. Chronic renal failure after liver transplantation. Am J Transplant 2005; 5: 967–968.Google Scholar
28.Winkelmayer, WC, Glynn, RJ, Levin, R, Avorn, J. Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 2003; 64: 1046–1049.CrossRefGoogle ScholarPubMed
29.Barron, ME, Wilkes, MM, Navickis, RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004; 139: 552–563.Google Scholar
30.Wiedermann, CJ. Hydroxyethyl starch – can the safety problems be ignored? Wien Klin Wochenschr 2004; 116: 583–594.Google Scholar
31.Boldt, J. Hydroxyethylstarch as a risk factor for acute renal failure: is a change of clinical practice indicated? Drug Saf 2002; 25: 837–846.CrossRefGoogle ScholarPubMed
32.Leuschner, J, Opitz, J, Winkler, A, Scharpf, R, Bepperling, F. Tissue storage of 14C-labeled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003; 4: 331–338.Google Scholar
33.Neff, TA, Doelberg, M, Jungheinrich, C, Sauerland, A, Spahn, DR, Stocker, R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003; 96: 1453–1459.Google Scholar
34.Boldt, J, Brenner, T, Lang, J, Kumle, B, Isgro, F. Kidney-specific proteins in elderly patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2003; 97: 1582–1589.CrossRefGoogle ScholarPubMed
35.Suttner, S, Boldt, J. Volume replacement with hydroxyethyl starch: is there an influence on kidney function? Anasthesiol Intensivmed Notfallmed Schmerzther 2004; 39: 71–77.Google Scholar
36.Sakr, Y, Payen, D, Reinhart, K et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 216–224.Google Scholar
37.Mahmood, A, Gosling, P, Vohra, K. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surgery 2007; 94: 427–433.Google Scholar